The European Commission (EC) has granted Fresenius Kabi the marketing authorization for Idacio, an adalimumab biosimilar, for all indications of...
Fresenius Kabi announced it has received FDA 510(k) clearance for the Aurora Xi Plasmapheresis System. The Aurora Xi Plasmapheresis System,...
Fresenius Kabi is seeking the European Commission’s approval for its tocilizumab biosimilar (MSB 11456) in both intravenous and subcutaneous routes of administration and it expects to receive both the EC’s and FDA’s approval in 2023.
Fresenius Kabi, a global health care company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, announced that the FDA has approved its citrate-free adalimumab biosimilar Idacio for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira(adalimumab)
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...